Optimer announces postive Phase II data

Optimer Pharmaceuticals has announced positive Phase III data from a trial of Prulifloxacin for infectious diarrhea. The drug, which is given in a once-daily dose, met the primary endpoint, and had a safety profile similar to that of a placebo. The study was conducted in Mexico and Peru, in patients who had traveler's diarrhea.

"We are encouraged by the positive data, which shows superiority of Prulifloxacin over placebo," said Michael Chang, President and CEO of Optimer Pharmaceuticals. "We believe these results provide a solid foundation for pursuing a New Drug Application with the FDA, assuming similar data from a second Phase 3 trial."

- here's Optimer's release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.